{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-26-000133","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.186665+00:00","generated_at":"2026-05-14T22:34:33.742468+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regenerex Pharma terminates CFO Kenneth Perry for cause; appoints Don E. Ray as interim CFO","bullets":["Kenneth Perry placed on administrative suspension with pay on March 31, 2026.","Board determined Perry's conduct constituted material breach and 'Cause' under employment agreement; termination effective May 2, 2026.","Don E. Ray appointed Interim CFO effective April 1, 2026 for an initial 90-day term.","CEO Greg Pilant recused himself from deliberations; independent board made decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-26-000133","json":"https://secwatch.observer/filing/0001472375-26-000133.json","markdown":"https://secwatch.observer/filing/0001472375-26-000133.md","text":"https://secwatch.observer/filing/0001472375-26-000133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:34:33.742468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b67dead347","claim":"Don E. Ray was appointed as Interim Chief Financial Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fa1b6e0798","claim":"Kenneth Perry was terminated as Chief Financial Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}